See more news releases in: Health Care & Hospitals, Medical Pharmaceuticals, FDA Approval
Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
Delsym is the only FDA-approved 12-hour non-prescription liquid cough
suppressant
CHESTER, N.J., Oct. 1 /PRNewswire-FirstCall/ -- Adams Respiratory
Therapeutics, Inc. (Nasdaq: ARxT) today announced that the Food and Drug
Administration (FDA) approved its supplemental New Drug Application for a
grape-flavored formulation of Delsym Extended-Release Suspension on Friday,
Sept. 28, 2007. The Company will immediately commence distribution of grape
Delsym product to its trade customers.
Delsym is the first and only over-the-counter (OTC) liquid that
controls cough for a full 12 hours with a single dose, providing all day or
all night cough suppression with each dose. Delsym's patented
single-ingredient formula delivers great tasting medicine in orange and now
new grape flavors for both children and adults.
About Adams Respiratory Therapeutics, Inc.
Adams is a specialty pharmaceutical company focused on the late-stage
development, commercialization and marketing of over-the-counter and
prescription pharmaceuticals for the treatment of respiratory disorders.
SOURCE Adams Respiratory Therapeutics, Inc.
Back to top
Custom Packages
Browse our custom packages or build your own to meet your unique communications needs.
PR Newswire Membership
Fill out a PR Newswire membership form or contact us at (888) 776-0942.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.
Featured Video
More in These Categories
Journalists and Bloggers
Visit PR Newswire for Journalists for releases, photos, ProfNet experts, and customized feeds just for Media.
View and download archived video content distributed by MultiVu on The Digital Center.
Free Investing Newsletter from Investor Uprising!
Learn to navigate the world's financial system and profit from leading companies.
Register for Investor Uprising, the people's investment site, for a free weekly newsletter, information, education and premium research including our latest IU Confidential Report - "All The Glitters: The Ultimate Gold Report".